Press releases
- Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
- Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
- Cybin to Participate at the 27th Annual Milken Institute Global Conference
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
- Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
- Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
- Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
- Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
More ▼
Key statistics
As of last trade, Cybin Inc (R7E1:MUN) traded at 0.3272, 47.39% above the 52 week low of 0.222 set on Jun 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3272 |
---|---|
High | 0.3272 |
Low | 0.3272 |
Bid | 0.3159 |
Offer | 0.3355 |
Previous close | 0.3272 |
Average volume | 4.75k |
---|---|
Shares outstanding | 743.89m |
Free float | 677.46m |
P/E (TTM) | -- |
Market cap | 350.40m CAD |
EPS (TTM) | -0.282 CAD |
Data delayed at least 15 minutes, as of May 23 2024 07:18 BST.
More ▼